carbenoxolone sodium has been researched along with Pulmonary Fibrosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, ZR; Li, L; Li, XZ; Liu, LQ; Ma, KT; Si, JQ; Wang, L; Zhang, LΖ | 1 |
1 other study(ies) available for carbenoxolone sodium and Pulmonary Fibrosis
| Article | Year |
|---|---|
Carbenoxolone decreases monocrotaline‑induced pulmonary inflammation and pulmonary arteriolar remodeling in rats by decreasing the expression of connexins in T lymphocytes.
Topics: Animals; Biopsy; Carbenoxolone; Connexin 43; Connexins; Cytokines; Disease Models, Animal; Echocardiography; Gene Expression Regulation; Hemodynamics; Immunophenotyping; Inflammation Mediators; Male; Monocrotaline; Pneumonia; Pulmonary Fibrosis; Rats; T-Lymphocytes; Vascular Remodeling | 2020 |